204 related articles for article (PubMed ID: 8656272)
1. Adjuvant interferon alfa-2b for high-risk melanoma.
Retsas S
J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
[No Abstract] [Full Text] [Related]
2. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
[No Abstract] [Full Text] [Related]
3. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
Johnson DM; Hayat SQ; Burton GV
J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
[No Abstract] [Full Text] [Related]
4. Adjuvant therapy of melanoma: at what cost?
Spitler LE
J Clin Oncol; 2001 Feb; 19(4):1226-8. PubMed ID: 11181688
[No Abstract] [Full Text] [Related]
5. Adjuvant IFN alpha2 therapy of melanoma.
Kirkwood JM
Lancet; 1998 Jun; 351(9120):1901-3. PubMed ID: 9654253
[No Abstract] [Full Text] [Related]
6. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant interferon in the treatment of melanoma.
Middleton MR
Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281
[No Abstract] [Full Text] [Related]
8. The adjuvant treatment of malignant melanoma.
Reintgen D; Kirkwood J
J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy of melanoma.
Retsas S
Lancet; 1998 Aug; 352(9129):737-8. PubMed ID: 9729017
[No Abstract] [Full Text] [Related]
10. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
[TBL] [Abstract][Full Text] [Related]
11. Clinical prognostic factors in adjuvant melanoma trial.
Nathanson L
J Clin Oncol; 1996 Jun; 14(6):1967-8. PubMed ID: 8656271
[No Abstract] [Full Text] [Related]
12. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
13. Interferon adjuvant therapy of melanoma.
Kirkwood JM; Wazer D; Rosenstein M
Cancer; 1997 May; 79(9):1843-6. PubMed ID: 9129006
[No Abstract] [Full Text] [Related]
14. Interferon for melanoma.
Richtig E; Langmann G
Ophthalmology; 2010 Sep; 117(9):1861. PubMed ID: 20816255
[No Abstract] [Full Text] [Related]
15. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
Kilbridge KL; Cole BF; Kirkwood JM; Haluska FG; Atkins MA; Ruckdeschel JC; Sock DE; Nease RF; Weeks JC
J Clin Oncol; 2002 Mar; 20(5):1311-8. PubMed ID: 11870174
[TBL] [Abstract][Full Text] [Related]
18. Patient preferences for adjuvant interferon alfa-2b treatment.
Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
[TBL] [Abstract][Full Text] [Related]
19. Melanoma: adjuvant therapy and other treatment options.
Terando A; Sabel MS; Sondak VK
Curr Treat Options Oncol; 2003 Jun; 4(3):187-99. PubMed ID: 12718796
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
